within Pharmacolibrary.Drugs.ATC.J;

model J01DC52
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 1.6666666666666667,
    adminDuration  = 600,
    adminMass      = 1.5,
    adminCount     = 1,
    Vd             = 0.014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Cefuroxime is a second-generation cephalosporin antibiotic used to treat various bacterial infections. Beta-lactamase inhibitors are combined with beta-lactam antibiotics to overcome resistance caused by beta-lactamase producing bacteria. The combination is aimed at enhancing efficacy against beta-lactamase producing pathogens. There is no current approved combination of cefuroxime with a beta-lactamase inhibitor widely marketed under the ATC code J01DC52.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies describing the parameters for the combination of cefuroxime and a beta-lactamase inhibitor were found. The following values are estimated based on known pharmacokinetic properties of intravenous cefuroxime in healthy adult subjects.</p><h4>References</h4><ol><li><p>Torumkuney, D, et al., &amp; Morrissey, I (2018). Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Greece. <i>The Journal of antimicrobial chemotherapy</i> 73(suppl_5) v36–v42. DOI:<a href=&quot;https://doi.org/10.1093/jac/dky068&quot;>10.1093/jac/dky068</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29659884/&quot;>https://pubmed.ncbi.nlm.nih.gov/29659884</a></p></li><li><p>Torumkuney, D, et al., &amp; Morrissey, I (2018). Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Russia. <i>The Journal of antimicrobial chemotherapy</i> 73(suppl_5) v14–v21. DOI:<a href=&quot;https://doi.org/10.1093/jac/dky065&quot;>10.1093/jac/dky065</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29659881/&quot;>https://pubmed.ncbi.nlm.nih.gov/29659881</a></p></li><li><p>Torumkuney, D, et al., &amp; Morrissey, I (2018). Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Ukraine and the Slovak Republic. <i>The Journal of antimicrobial chemotherapy</i> 73(suppl_5) v28–v35. DOI:<a href=&quot;https://doi.org/10.1093/jac/dky069&quot;>10.1093/jac/dky069</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29659885/&quot;>https://pubmed.ncbi.nlm.nih.gov/29659885</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01DC52;
